Impact of Bivalirudin on Ischemia/Reperfusion Injury in Patients with Reperfused STEMI Assessed by Cardiac Magnetic Resonance
Zhang Y, Zou Z, Xu B, Chen B, Ge H, Ding S, Pu J (2024) · Pharmaceuticals · n=42
Studienprofil
- Design
- small prospective comparative study (n=42) of bivalirudin vs unfractionated heparin in primary PCI for STEMI patients, with serial cardiac magnetic resonance imaging at acute, 1-month, and 3-month follow-up; EARLY Assessment of Myocardial Tissue Characteristics by CMR in STEMI registry (NCT03768453, Shanghai Renji Hospital)
- Stichprobengröße (n)
- 42
- Intervention
- Bivalirudin (n=21) for STEMI primary PCI anticoagulation
- Komparator
- Unfractionated heparin (n=21) for STEMI primary PCI anticoagulation
- Primärer Endpunkt
- Myocardial edema volume, microvascular obstruction (MVO) volume/incidence, and intramyocardial hemorrhage (IMH) incidence on CMR
- Primäres Ergebnis
- Bivalirudin group: significantly less acute myocardial edema; only 4.7% had edema at 1 month vs 33.3% in heparin group; complete edema resolution by 3 months vs persistence in heparin group; significantly lower MVO incidence/volume acutely; significantly lower IMH incidence acutely and at follow-up; corroborated by T2/T1 mapping; bivalirudin associated with attenuated ischemia/reperfusion injury
- Follow-up-Dauer
- 3 months (serial CMR)
- PMID
- 38399411
Wichtigste Ergebnisse
- CMR-quantified myocardial edema, MVO, and IMH all significantly reduced with bivalirudin vs heparin
- Bivalirudin appears to reduce ischemia/reperfusion injury at the tissue level
- First imaging-endpoint corroboration of bivalirudin tissue-protective effects in STEMI
- n=21 per arm — small but adequately powered for primary CMR endpoints
- Reinforces drug-pathway development of synthetic hirudin derivatives
Einschränkungen
- Small sample (n=42 total)
- Single-center registry-based design
- Open-label (no blinding)
- Outcomes are imaging surrogates, not hard clinical endpoints
- Not generalizable beyond STEMI patient population
Klinische Implikationen
Zhang 2024 adds imaging-based mechanistic evidence to the bivalirudin literature. For ASH, the trial serves as a pharmacology and regulatory reference for distinguishing FDA-approved synthetic hirudin-derivative drug indications (bivalirudin in STEMI) from the K040187 device indication (whole-leech hirudotherapy in microsurgical flap salvage). Not directly applicable to US hirudotherapy clinical practice.
Verwandte Studien
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, Cannon CP (1995)
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)
Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps
Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)
Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024)